Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis

BACKGROUND: Tofacitinib, an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA), provides patients with an alternative to subcutaneously or intravenously administered biologic disease-modifying antirheumatic drugs (DMARDs). Little is known about patient preference for...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Am Health Drug Benefits
Main Authors: Louder, Anthony M., Singh, Amitabh, Saverno, Kim, Cappelleri, Joseph C., Aten, Aaron J., Koenig, Andrew S., Pasquale, Margaret K.
Format: Artigo
Jezik:Inglês
Izdano: Engage Healthcare Communications, LLC 2016
Teme:
Clinical
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4856233/
https://ncbi.nlm.nih.gov/pubmed/27182427
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki